Metrics as of 10/16/2026, 11:52 AM (Berlin time), refresh in progress.
Enlivex Therapeutics Stock
Enlivex Therapeutics Ltd.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- CEO
- Oren Hershkovitz
- Employees
- 34
- Market cap
- $4 M
- IPO
- 31/07/2014
Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical…
Enlivex Therapeutics stock: price history
1D
+4.0%
1W
-19.1%
1M
-74.6%
6M
-98.3%
YTD
-97.9%
1Y
-98.7%
2Y
-99.0%
5Y
-99.8%
10Y
-100.0%
Next earnings date
Next earnings date
13/11/2026 (in 27 days)
Volatility around earnings
~4% weaker price swings than usual
Ask the agents about Enlivex Therapeutics
Analyst assessment of Enlivex Therapeutics
PRICE TARGET LOW
US$15.00
CONSENSUS
US$15.00
MEDIAN
US$15.00
PRICE TARGET HIGH
US$15.00
0
STRONG BUY
3
BUY
1
HOLD
0
SELL
0
STRONG SELL
4
TOTAL · Buy
As of: 03/08/2026
Enlivex Therapeutics stock metrics
P/E
0
P/B
0
EV/EBITDA
-0.78
RETURN ON EQUITY
48.5%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
99.5%
FLOAT SHARES
16,747,025
AVG. DAILY VOLUME (30D)
1,782,775
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Enlivex Therapeutics stock
What does Enlivex Therapeutics do?
Enlivex Therapeutics Ltd. is a company in the Healthcare sector, Biotechnology industry, headquartered in Israel.
The CEO is Oren Hershkovitz, the company employs around 34 people.
The IPO was on 31/07/2014; the stock trades on NASDAQ under the ticker ENLV.
What do analysts say about Enlivex Therapeutics stock?
4 analysts rate the stock, the consensus is Buy (as of 03/08/2026).
The average price target is US$15.00, ranging from US$15.00 to US$15.00, with a median of US$15.00.
This is an external assessment, not a statement by Market Jury.
When does Enlivex Therapeutics report next?
The next earnings date is 13/11/2026.
Around past earnings, price swings were roughly -4% stronger than usual.
Does Enlivex Therapeutics pay a dividend?
No, Enlivex Therapeutics currently does not pay a dividend.
Which stocks are comparable to Enlivex Therapeutics?
Comparable stocks include Alpha Tau Medical, Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines and Incyte.
How can I get Enlivex Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Enlivex Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.